iOmx Therapeutics Initiates Phase Ib with OMX-0407
August 22, 2024 04:00 ET
|
iOmx Therapeutics AG
Data from the successful Phase Ia dose escalation study showed that OMX-0407 monotherapy demonstrated a favorable safety profile and signs of anti-tumor activity, with one durable complete response in...
Turnstone Biologics Corp. Reports Positive Initial Data from Phase 1 Trial of TIDAL-01 in Metastatic Colorectal Cancer
August 14, 2024 16:01 ET
|
Turnstone Biologics Corp.
ORR of 25% and 50% DCR observed in first four evaluable patients treated with TIDAL-01 with advanced CRC
Monopar Announces Initial Data for First Patient Dosed in Radiopharma Phase 1 Clinical Trial of MNPR-101-Zr
August 14, 2024 08:00 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients,...
Opioid Overdose Cases Show Presence of Medetomidine, Veterinary Medicine Similar to Xylazine, According to Recent Study by the Toxicology Investigators Consortium
August 01, 2024 14:16 ET
|
American College of Medical Toxicology
Phoenix, AZ, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Data gathered by the Toxicology Investigators Consortium (ToxIC) Fentalog Study was reported in the CDC’s August 1, 2024 Morbidity and Mortality Weekly...
Chemomab Therapeutics Announces Closing of $10 Million Private Placement
July 30, 2024 09:00 ET
|
Chemomab Therapeutics
Chemomab closed a $10 million PIPE financing that included new and existing top tier investors and extends the cash runway through the beginning of 2026
Longeveron® Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ in Mild Alzheimer’s Disease at the Alzheimer’s Association International Conference® (AAIC)
July 28, 2024 16:51 ET
|
Longeveron
Longeveron Phase 2a clinical results in Alzheimer's Disease selected for Featured Research oral presentation at Alzheimer’s Association International Conf
Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis
July 25, 2024 07:00 ET
|
Chemomab Therapeutics
Chemomab reported positive topline results from Ph 2 trial assessing CM-101 in PSC. Achieved safety endpoint and improved wide range of secondary endpoints
Global Electronic Clinical Outcome Assessment Solution Market Analysis Report 2024-2029: Surging Adoption Owing to Increasing Number of Clinical Trials in Emerging Economies
March 18, 2024 07:10 ET
|
Research and Markets
Dublin, March 18, 2024 (GLOBE NEWSWIRE) -- The "Global Electronic Clinical Outcome Assessment (eCOA) Solution Market by Modality (Wearable, Mobile, BYOD), Type (PRO, CLINRO, OBSRO, PERFO), Use...
Clinical Data Analytics Solutions Market Report 2024, with Profiles of Optum, SAS Institute, IQVIA, Health Catalyst, eClinical Solutions, JMP Statistical Discovery, OSP, BD, Dassault and Cognizant
March 18, 2024 05:29 ET
|
Research and Markets
Dublin, March 18, 2024 (GLOBE NEWSWIRE) -- The "Clinical Data Analytics Solutions Market Size, Share & Trends Analysis Report By Deployment (Cloud-based, On-premise), By Application (Clinical...
SeaStar Medical-Sponsored Symposium Featuring Experts Discussing Pediatric Acute Kidney Injury and the Selective Cytopheretic Device to be Webcast Live at AKI & CRRT 2024
March 11, 2024 16:05 ET
|
SeaStar Medical Holding Corporation
March 13 webcast showcasing Quelimmune™ scientific background and clinical data for pediatric AKI due to sepsis or a septic condition will be available on seastarmedical.com DENVER, March 11, 2024...